Michal Votruba Net Worth

Michal Votruba biography

Dr. Michal Votruba M.D., Ph.D. serves as Independent Director of the Company. Since 2013, Dr. Votruba has been a Director of the Gradus/RSJ Life Sciences Fund, the largest dedicated fund in Central Europe with a portfolio of companies in Europe and the United States. Dr. Votruba has served as a director of Mynd Anlaytics, Inc., a telebehavioral health services company, since July 2015. Since 2010, he has served as a member of the board of PrimeCell Therapeutics as the Director of Global Business Development overseeing the expansion of the largest regenerative medicine company operating in Central Europe. In 2009, the Czech Academy of Sciences solicited Dr. Votruba's expertise for the first successful privatization project of the Institute of Experimental Medicine in Prague: the newly created protocol established a precedent for future privatization projects in the Czech Republic. Dr. Votruba graduated as a Clinical Psychiatrist from the Medical Faculty of Charles University in Prague in 1989. Shortly thereafter, he emigrated from Czechoslovakia and developed his professional career in Canada and the USA. Since 2005, Dr. Votruba combined his theoretical and clinical experience in the field of Competitive Intelligence serving the global pharmaceutical industry for eight years as an industry analyst advising senior leaders of companies including Amgen, Novartis, Eli Lilly, Allergan, EMD, Serono and Sanofi. Dr. Votruba brings valuable expertise to the Board of Directors as a clinical psychiatrist and broad experience in the international marketing of innovative medical technologies.

What is the salary of Michal Votruba?

As the Independent Director of BioXcel Therapeutics Inc, the total compensation of Michal Votruba at BioXcel Therapeutics Inc is $136,668. There are 8 executives at BioXcel Therapeutics Inc getting paid more, with Vimal Mehta having the highest compensation of $1,968,930.

How old is Michal Votruba?

Michal Votruba is 54, he's been the Independent Director of BioXcel Therapeutics Inc since 2019. There are 9 older and 5 younger executives at BioXcel Therapeutics Inc. The oldest executive at BioXcel Therapeutics Inc is Dr. Frank D. Yocca Ph.D., 65, who is the Sr. VP & Chief Scientific Officer.

What's Michal Votruba's mailing address?

Michal's mailing address filed with the SEC is C/O BIOXCEL THERAPEUTICS, INC.,, 555 LONG WHARF DRIVE, NEW HAVEN, CT, 06511.

Insiders trading at BioXcel Therapeutics Inc

Over the last 7 years, insiders at BioXcel Therapeutics Inc have traded over $63,244,788 worth of BioXcel Therapeutics Inc stock and bought 45,656 units worth $321,105 . The most active insiders traders include Vimal Bio Xcel Holdings, In..., Vimal Mehta és Krishnan Nandabalan. On average, BioXcel Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $29,814. The most recent stock trade was executed by Matthew T. Wiley on 15 June 2024, trading 750 units of BTAI stock currently worth $413.

What does BioXcel Therapeutics Inc do?

bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

BioXcel Therapeutics Inc executives and stock owners

BioXcel Therapeutics Inc executives and other stock owners filed with the SEC include:

• Vimal Mehta,
  President, Chief Executive Officer, Co-Founder, Secretary, Director
• Dr. Vimal D. Mehta Ph.D.,
  Founder, CEO, Pres, & Director
• Frank Yocca,
  Chief Scientific Officer
• Vincent O'Neill,
  Chief Medical Officer
• Richard Steinhart,
  Chief Financial Officer
• Peter Mueller,
  Independent Chairman of the Board
• Sandeep Laumas,
  Independent Director
• Dr. Krishnan Nandabalan,
  Chief Digital Officer ?& Director
• Michal Votruba,
  Independent Director
• John Graziano,
  IR Contact Officer
• Reina Benabou,
  Senior Vice President, Chief Development Officer
• Will Kane,
  Executive Vice President, Chief Commercial Officer
• Krishnan Nandabalan,
  Co-Founder, Director, Chief Digital Officer
• Matthew Wiley,
  Sr. VP & Chief Commercial Officer
• Dr. Iris Francesconi Ph.D.,
  Sr. VP of Marketing, Market Research & Commercial Assessments
• Dr. Frank D. Yocca Ph.D.,
  Sr. VP & Chief Scientific Officer
• Richard I. Steinhart MBA,
  Sr. VP & CFO
• Dr. Reina Benabou M.D., Ph.D.,
  Sr. VP & Chief Devel. Officer
• William P. Kane Jr.,
  Exec. VP & Chief Commercial Officer
• Dr. David C. Hanley,
  Head of Global Pharmaceutical Devel. and Operations & VP
• Dr. Cedric Burg,
  VP and Head of Global Clinical Operations & Project Management
• Javier Rodriguez,
  Sr. VP, Chief Legal Officer & Corp. Sec.
• Mary Coleman,
  VP of Investment Relations
• Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P.,
  Sr. VP & Chief Medical Officer
• Llc Bio Xcel,
  10% owner
• Holdings, Inc. Bio Xcel,
  10% owner
• Matthew T. Wiley,
  Chief Commercial Officer
• Michael Patrick Miller,
  Director
• June Bray,
  Director
• Vimal Bio Xcel Holdings, In...,
  CEO and President